Reviewing Cingulate (NASDAQ:CING) and BioGaia AB (publ) (OTCMKTS:BIOGY)

Cingulate (NASDAQ:CING) and BioGaia AB (publ) (OTCMKTS:BIOGY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Profitability

This table compares Cingulate and BioGaia AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
BioGaia AB (publ)	N/A	N/A	N/A

Insider & Institutional Ownership

41.3% of Cingulate shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Cingulate and BioGaia AB (publ), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1	0	3	0	2.50
BioGaia AB (publ)	0	0	0	0	0.00

Cingulate presently has a consensus target price of $27.00, indicating a potential upside of 422.24%. Given Cingulate’s stronger consensus rating and higher probable upside, research analysts plainly believe Cingulate is more favorable than BioGaia AB (publ).

Valuation and Earnings

This table compares Cingulate and BioGaia AB (publ)”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45 million	($3.59)	-1.44
BioGaia AB (publ)	N/A	N/A	N/A	$4.20	2.96

Cingulate is trading at a lower price-to-earnings ratio than BioGaia AB (publ), indicating that it is currently the more affordable of the two stocks.

Summary

Cingulate beats BioGaia AB (publ) on 5 of the 9 factors compared between the two stocks.

About Cingulate

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

About BioGaia AB (publ)

BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is based in Stockholm, Sweden.